Cited by 152Alzheimer's disease research and treatmentsAutophagy in Disease and TherapyParkinson's Disease Mechanisms and Treatments

Nilotinib-induced autophagic changes increase endogenous parkin level and ubiquitination, leading to amyloid clearance

Open access
Lonskaya, Irina, Hebron, Michaeline L., Desforges, Nicole M., Schachter, Joel B., Moussa, Charbel E-H·2014·Journal of Molecular Medicine

Abstract

Unlabelled Alzheimer's disease (AD) is a neurodegenerative disorder associated with amyloid accumulation and autophagic changes. Parkin is an E3 ubiquitin ligase involved in proteasomal and autophagic clearance. We previously demonstrated decreased parkin solubility and interaction with the key autophagy enzyme beclin-1 in AD, but tyrosine kinase inhibition restored parkin-beclin-1 interaction. In the current studies, we determined the mechanisms of nilotinib-induced parkin-beclin-1 interaction, which leads to amyloid clearance. Nilotinib increased endogenous parkin levels and ubiquitination, which may enhance parkin recycling via the proteasome, leading to increased activity and interaction with beclin-1. Parkin solubility was decreased and autophagy was altered in amyloid expressing mice, suggesting that amyloid stress affects parkin stability, leading to failure of protein clearance via the lysosome. Isolation of autophagic vacuoles revealed amyloid and parkin accumulation in autophagic compartments but nilotinib decreased insoluble parkin levels and facilitated amyloid deposition into lysosomes in wild type, but not parkin(-/-) mice, further underscoring an essential role for endogenous parkin in amyloid clearance. These results suggest that nilotinib boosts the autophagic machinery, leading to increased level of endogenous parkin that undergoes ubiquitination and interacts with beclin-1 to facilitate amyloid clearance. These data suggest that nilotinib-mediated autophagic changes may trigger parkin response via increased protein levels, providing a therapeutic strategy to reduce Aβ and Tau in AD.Key message Parkin solubility (stability) is decreased in AD and APP transgenic mice. Nilotinib-induced autophagic changes increase endogenous parkin level. Increased parkin level leads to ubiquitination and proteasomal recycling. Re-cycling decreases insoluble parkin and increases parkin-beclin-1 interaction. Beclin-1-parkin interaction enhances amyloid clearance.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00109-013-1112-3

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 46 · Cited by 152

Authors
Lonskaya, I., Hebron, M. L., Desforges, N. M., Schachter, J. B., & Moussa, C. E.-H.
Affiliations
  • Georgetown University Medical Center (US)
  • Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Corresponding author
Moussa, Charbel E-H
Venue
Journal of Molecular Medicine
Published
2013-12-13
Volume
92
Issue
4
Pages
373-386
ISSN
  • 0946-2716 (ISSN-L)
  • 1432-1440
OpenAlex
W2015808257
Cited by
152
References
46
Citations by year
2026: 3 · 2025: 13 · 2024: 12 · 2023: 12 · 2022: 15 · 2021: 19 · 2020: 17 · 2019: 15 · 2018: 15 · 2017: 11 · 2016: 8 · 2015: 6 · 2014: 6
FWCI
4.64
Type
journal article
Language
en
Open access
Locations
  • Journal of Molecular Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Merck
  • Georgetown University
  • National Institutes of Health
  • U.S. Public Health Service (30378)
  • National Institute on Aging (K01AG030378)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Epidemiology › Autophagy in Disease and Therapy
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
Keywords
nilotinib, Alzheimer's disease, Parkin, Beclin-1, autophagy, amyloid-beta clearance, ubiquitination, tyrosine kinase inhibition, APP transgenic mice, lysosomal clearance
MeSH terms
Alzheimer Disease, Amyloid, Animals, Autophagy, Enzyme Stability, Hippocampus, Humans, Male, Mice, Inbred C57BL, Mice, Transgenic, Pyrimidines, Ubiquitin-Protein Ligases, Cell Line, Tumor, Protein Kinase Inhibitors, Rats, Ubiquitination

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review